Laura Capolongo

Influence of structural modifications at the 3' and 4' positions of doxorubicin on the drug ability to trap topoisomerase II and to overcome multidrug resistance.

Giovanni Capranico, Rosanna Supino, Monica Binaschi et al. · Molecular Pharmacology · 1994 · 66 citations

Medicine, Medicinal Chemistry, Pharmacology +16

Biological profile of FCE 24517, a novel benzoyl mustard analogue of distamycin A

Gabriella Pezzoni, Maria Grandi, Giovanni Biasoli et al. · British Journal of Cancer · 1991 · 64 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +5

A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy

Gautam Borthakur, Hervé Dombret, Philippe Schafhausen et al. · Haematologica · 2015 · 58 citations · Full text

Medicine, Oncology, Pharmacology +16

PHA-739358, an Aurora Kinase Inhibitor, Induces Clinical Responses in Chronic Myeloid Leukemia Harboring T315I Mutations of BCR-ABL.

Ronald Paquette, Neil P. Shah, Charles L. Sawyers et al. · Blood · 2007 · 53 citations

Medicine, Hematology, Oncology +9

Danusertib Hydrochloride (PHA-739358), a Multi-Kinase Aurora Inhibitor, Elicits Clinical Benefit in Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia .

Jörge E. Cortes, Hervé Dombret, Philippe Schafhausen et al. · Blood · 2009 · 44 citations

Medicine, Oncology, Pharmacology +15